secwatch.observer — SEC 8-K summary
======================================

Issuer:     UroGen Pharma Ltd. (URGN)
CIK:        0001668243
Form:       8-K
Filed at:   2022-03-21T23:59:59+00:00
Accession:  0001193125-22-080081
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

UroGen Pharma CFO resigns; reports FY2021 Jelmyto revenue $48M, net loss $110.8M
--------------------------------------------------------------------------------

- CFO Molly Henderson resigns effective March 25, 2022; replaced by Dong Kim (VP Finance).
- FY2021 Jelmyto net product revenue $48.0M, up 307% YoY; Q4 revenue $16.2M, up 42% QoQ.
- FY2021 net loss $110.8M ($4.96/share) vs $128.5M loss in prior year.
- 2022 revenue guidance $70-80M; operating expenses guided $140-160M; RTW financing expense $22-26M.
- Closed $75M tranche of up to $100M senior secured term loan facility with Pharmakon Advisors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1668243/000119312522080081/0001193125-22-080081-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1668243/000119312522080081/d258593d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-080081

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer